Select Publications

Alberts DS et al. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol Oncol 2006;103(3):783-92. Abstract

Bookman MA, for the Gynecologic Cancer InterGroup (GCIG). GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Proc ASCO 2006;Abstract 5002.

Bookman MA. Standard treatment in advanced ovarian cancer in 2005: The state of the art. Int J Gynecol Cancer 2005;15(Suppl 3):212-20. Abstract

Bookman MA et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003a;21(2):283-90. Abstract

Bookman MA et al. Optimal therapy of advanced ovarian cancer: Carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 2003b;13(6):735-40. Abstract

Burger RA et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. Proc ASCO 2005;Abstract 5009.

Cannistra SA et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25(33):5180-6. Abstract

Cannistra SA et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Proc ASCO 2006;Abstract 5006.

Du Bois A et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol 2006;24(7):1127-35. Abstract

Gordon MS et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24(26):4324-32. Abstract

Han ES et al. Relationship of angiogenesis biomarkers and clinical response to bevacizumab (Bev) in persistent or recurrent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) patients treated in a Phase II Gynecologic Oncology Group study. Proc ASCO 2007;Abstract 21021.

Makhija S et al. Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Proc ASCO 2007;Abstract 5507.

Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 2000;27(3 Suppl 7):3-7. Abstract

Parmar MK et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361(9375):2099-106. Abstract

Pfisterer J et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24(29):4699-707. Abstract

Wright JD et al. A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer. Proc ASCO 2006;Abstract 5019.

Home

EDITOR
Neil Love, MD

INTERVIEWS

Robert F Ozols, MD, PhD
- Select publications

Maurie Markman, MD
- Select publications

Thomas J Herzog, MD
- Select publications

Ovarian Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office